Dr. Camidge joined the University of Colorado as a visiting professor in November of 2005 and was recruited as full-time faculty in October of 2007. He is dual-trained in both medical oncology and clinical pharmacology.
Dr. Camidge is the Director of Thoracic Oncology at the University of Colorado. His focus is in Thoracic Malignancies and Developmental Therapeutics (Phase I studies). In 2012 he was announced as the recipient of the Bonnie J. Addario International Lectureship Award as a ‘Luminary in the quest to eradicate lung cancer.’ In 2013 he became the first physician to receive the Hank Baskett Sr. Spirit Award, for which he was credited as being ‘one of the leading minds in lung cancer today.’ In 2014, he was nationally recognized by The Quality of Life Center at Claremont University in California as an ‘Exemplary mentor in the positive development of junior colleagues in the profession.’ In 2016, the Lung Cancer Foundation presented him with the Breath Away From The Cure Award describing him as ‘Simply one of the best in treating lung cancer today.’ In both 2017 and 2018, he was recognized as a Highly Cited Researcher in Clarivate’s Web of Science, ranking among the top 1% of clinical medicine researchers internationally.
Dr. Camidge is also the National Medical Director of the Academic Thoracic Oncology Medical Investigators Consortium (ATOMIC) and a past member of the National Comprehensive Cancer Network (NCCN) Lung Cancer, Mesothelioma and Thymic Cancer Committees.
Dr. Camidge has been principal investigator on numerous clinical trials in early phase drug development and thoracic malignancies. He has authored more than 150 articles and reviews in peer-reviewed journals such as Cancer, Journal of Clinical Oncology, Journal of Thoracic Oncology and The New England Journal of Medicine. His work has repeatedly helped to change the standard of care in the treatment of lung and other thoracic cancers. He has presented his research at multiple national and international scientific meetings.